Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

In today’s fast-paced world, maintaining optimal health and wellness can often feel like a daunting task. With the prevalence ...

The 74 interviews an emergency physician and a legal medical expert to better understand the pediatric and school-based ...

Trump's Republicans reelect Mike Johnson US House Speaker despite dissent ...

Healthcare stocks, especially biopharmaceuticals, are forecasted to outperform the market due to four key investment themes.

In the ever-evolving world of weight loss supplements, finding a product that truly lives up to its promises can feel like ...